`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`REGENERON PHARMACEUTICALS, INC.,
`Petitioner
`v.
`NOVARTIS PHARMA AG,
`NOVARTIS TECHNOLOGY LLC,
`NOVARTIS PHARMACEUTICALS CORPORATION,
`Patent Owners
`
`
`Case IPR2021-00816
`Patent 9,220,631
`
`
`SECOND MODIFIED DEFAULT PROTECTIVE ORDER
`
`
`
`Novartis Exhibit 2323.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`SECOND MODIFIED DEFAULT PROTECTIVE ORDER
`
`This protective order governs the treatment and filing of confidential and
`
`Outside Counsel Only information, including documents and testimony.
`
`1.
`
`Confidential information shall be clearly marked “CONTAINS
`
`CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE
`
`ORDER.”
`
`2.
`
`Access to confidential information is limited to the following
`
`individuals who have executed the acknowledgment appended to this order:
`
`(A) Party Representatives. Representatives of record for a party in the
`
`proceeding.
`
`(B) Experts. Retained experts of a party in the proceeding who further
`
`certify in the Acknowledgement that they are not a competitor to any
`
`party, or a consultant for, or employed by, such a competitor with
`
`respect to the subject matter of the proceeding.
`
`(C)
`
`In-house counsel. Two in-house counsel representatives of a party.
`
`(D) Support Personnel. Administrative assistants, clerical staff, court
`
`reporters and other support personnel of the foregoing persons who
`
`are reasonably necessary to assist those persons in the proceeding
`
`shall not be required to sign an Acknowledgement, but shall be
`
`
`
`Novartis Exhibit 2323.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`informed of the terms and requirements of the Protective Order by the
`
`person they are supporting who receives confidential information.
`
`(E) The Office. Employees and representatives of the United States
`
`Patent and Trademark Office who have a need for access to the
`
`confidential information shall have such access without the
`
`requirement to sign an Acknowledgement. Such employees and
`
`representatives shall include the Director, members of the Board and
`
`their clerical staff, other support personnel, court reporters, and other
`
`persons acting on behalf of the Office.
`
`3.
`
`Outside Counsel Only information shall be clearly marked
`
`“CONTAINS OUTSIDE COUNSEL ONLY INFORMATION, SUBJECT TO
`
`PROTECTIVE ORDER.” Outside Counsel Only information includes documents
`
`produced by Third Parties in Certain Pre-Filled Syringes for Intravitreal Injection
`
`& Components Thereof, ITC Investigation No. 337-TA-1207 (“the ITC
`
`Investigation”), deposition transcripts of Third Party witnesses in the ITC
`
`Investigation and exhibits thereto, and declarations of Third Party witnesses in the
`
`ITC Investigation.
`
`4.
`
`Access to Outside Counsel Only information is limited to the
`
`following individuals who have executed the acknowledgement appended to this
`
`order:
`
`
`
`Novartis Exhibit 2323.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`(A) Party Representatives. Representatives of record for a party in the
`
`proceeding, excluding any in-house counsel who are of record.
`
`(B) Experts. Retained experts of a party in the proceeding who further
`
`certify in the Acknowledgement that they are not a competitor to any
`
`party, or a consultant for, or employed by, such a competitor with
`
`respect to the subject matter of the proceeding.
`
`(C) Support Personnel. Administrative assistants, clerical staff, court
`
`reporters and other support personnel of the foregoing persons who
`
`are reasonably necessary to assist those persons in the proceeding
`
`shall not be required to sign an Acknowledgement, but shall be
`
`informed of the terms and requirements of the Protective Order by the
`
`person they are supporting who receives Outside Counsel Only
`
`information.
`
`(D) The Office. Employees and representatives of the United States Patent
`
`and Trademark Office who have a need for access to the confidential
`
`information shall have such access without the requirement to sign an
`
`Acknowledgement. Such employees and representatives shall include
`
`the Director, members of the Board and their clerical staff, other
`
`support personnel, court reporters, and other persons acting on behalf
`
`of the Office.
`
`
`
`
`
`Novartis Exhibit 2323.004
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`5.
`
`Employees (e.g., corporate officers), consultants, or other persons
`
`performing work for a party, other than those persons identified above in 2(A)–(D)
`
`or 4(A)- (C), shall be extended access to confidential and Outside Counsel Only
`
`information, respectively, only upon agreement of the parties (including agreement
`
`by any Third Party in the case of Outside Counsel Only Information) or by order
`
`of the Board upon a motion brought by the party seeking to disclose confidential
`
`information to that person and after signing the Acknowledgment. The party
`
`opposing disclosure to that person shall have the burden of proving that such
`
`person should be restricted from access to confidential or Outside Counsel Only
`
`information.
`
`6.
`
`Persons receiving confidential or Outside Counsel Only information
`
`shall use reasonable efforts to maintain the confidentiality of the information,
`
`including:
`
`(A) Maintaining such information in a secure location to which persons
`
`not authorized to receive the information shall not have access;
`
`(B) Otherwise using reasonable efforts to maintain the confidentiality of
`
`the information, which efforts shall be no less rigorous than those the
`
`recipient uses to maintain the confidentiality of information not
`
`received from the disclosing party;
`
`
`
`Novartis Exhibit 2323.005
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`(C) Ensuring that support personnel of the recipient who have access to
`
`the confidential information understand and abide by the obligation to
`
`maintain the confidentiality of information received that is designated
`
`as confidential; and
`
`(D) Limiting the copying of confidential or Outside Counsel Only
`
`information to a reasonable number of copies needed for conduct of
`
`the proceeding and maintaining a record of the locations of such
`
`copies.
`
`7.
`
`Persons receiving confidential or Outside Counsel Only information
`
`shall use the following procedures to maintain the confidentiality of the
`
`information:
`
`(A) Documents and Information Filed With the Board.
`
`(i) A party may file documents or information with the Board
`
`along with a Motion to Seal. The Motion to Seal should provide a
`
`non-confidential description of the nature of the confidential
`
`information that is under seal, and set forth the reasons why the
`
`information is confidential and should not be made available to the
`
`public. A party may challenge the confidentiality of the information
`
`by opposing the Motion to Seal. The documents or information shall
`
`
`
`Novartis Exhibit 2323.006
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`remain under seal unless the Board determines that some or all of it
`
`does not qualify for confidential treatment.
`
`(ii) Where confidentiality is alleged as to some but not all of the
`
`information submitted to the Board, the submitting party shall file
`
`confidential and non-confidential versions of its submission, together
`
`with a Motion to Seal the confidential or Outside Counsel Only
`
`version setting forth the reasons why the information redacted from
`
`the non-confidential version is confidential or designated Outside
`
`Counsel Only and should not be made available to the public. A party
`
`may challenge the confidentiality of the information by opposing the
`
`Motion to Seal. The non-confidential version of the submission shall
`
`clearly indicate the locations of information that has been redacted.
`
`The confidential or Outside Counsel Only version of the submission
`
`shall be filed under seal. The redacted information shall remain under
`
`seal unless the Board determines that some or all of the redacted
`
`information does not qualify for confidential or Outside Counsel Only
`
`treatment.
`
`(B) Documents and Information Exchanged Among the Parties.
`
`Documents (including deposition transcripts) and other information
`
`designated as confidential that are disclosed to another party during
`
`
`
`
`
`Novartis Exhibit 2323.007
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`discovery or other proceedings before the Board shall be clearly
`
`marked as “CONTAINS CONFIDENTIAL BUSINESS
`
`INFORMATION, SUBJECT TO PROTECTIVE ORDER” and shall
`
`be produced in a manner that maintains its confidentiality.
`
`Documents (including deposition transcripts) and other information
`
`designated as Outside Counsel Only that are disclosed to another party
`
`during discovery or other proceedings before the Board shall be
`
`clearly marked as “OUTSIDE COUNSEL ONLY, SUBJECT TO
`
`PROTECTIVE ORDER” and shall be produced in a manner that
`
`maintains its confidentiality.
`
`8. Within 60 days after the final disposition of this action, including the
`
`exhaustion of all appeals and motions, each party receiving confidential
`
`information must return, or certify the destruction of, all copies of the confidential
`
`information to the producing party.
`
`
`
`
`
`
`
`Novartis Exhibit 2323.008
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`Standard Acknowledgment for Access to Protective Order Material
`
`I __________________________________________________, affirm that
`
`I have read the Protective Order; that I will abide by its terms; that I will use the
`
`confidential information only in connection with this proceeding and for no other
`
`purpose; that I will only allow access to support staff who are reasonably necessary
`
`to assist me in this proceeding; that prior to any disclosure to such support staff I
`
`informed or will inform them of the requirements of the Protective Order; that I am
`
`personally responsible for the requirements of the terms of the Protective Order
`
`and I agree to submit to the jurisdiction of the Office and the United States District
`
`Court for the Eastern District of Virginia for purposes of enforcing the terms of the
`
`Protective Order and providing remedies for its breach.
`
`
`
`
`
`Date:
`
`
`
`Novartis Exhibit 2323.009
`Regeneron v. Novartis, IPR2021-00816
`
`